Objectives: The aim of this study was to investigate the single-and multiple-dose pharmacokinetics (PK) of moxifloxacin and its penetration into ascitic fluid in patients with severe liver insufficiency (Child -Pugh class C).
Introduction
Severe bacterial infections such as spontaneous bacterial peritonitis, pneumonia or sepsis are well-described life-limiting complications in patients with advanced liver cirrhosis. 1 Pharmacological and microbiological characteristics make moxifloxacin an attractive option in the treatment of severe bacterial infections independently of the infection site. 2 On the other hand, since moxifloxacin is predominantly metabolized by the liver, a theoretical drug accumulation cannot be excluded in patients with advanced liver insufficiency. 3 Owing to the lack of appropriate pharmacokinetic data, the use of moxifloxacin is currently not recommended in this patient population. 4 The purpose of this study was to document the pharmacokinetic profile of intravenous moxifloxacin in patients with severe hepatic impairment (ChildPugh class C) after single and multiple dosing. In addition, we investigated the ability of the drug to penetrate into ascitic fluid at the site of infection in spontaneous bacterial peritonitis.
Patients and methods

Study design and subjects
This single-centre, prospective, open-label study was performed on a cohort of nine adult patients with alcoholic liver cirrhosis and I.V., Bayer HealthCare AG, Wuppertal, Germany) over 1 h once daily for pneumonia (n ¼ 3) or spontaneous bacterial peritonitis (n ¼ 6), irrespective of their body weight, age and sex. Exclusion criteria were: child-bearing potential, pregnancy, lactation, a severely immunocompromised status, use of any antibacterial agent 4 weeks before study entry, severe renal impairment (creatinine clearance ,30 mL/min/1.73 m 2 or haemodialysis), significant cardiovascular disease, severe psychiatric disease, a history of drug abuse and known allergy to fluoroquinolones. All patients were given a detailed description of the study, and their written consent was obtained. The protocol of the study was approved by the local institutional review board. The study was performed in accordance with the Declaration of Helsinki and the Good Clinical Practice Guideline of the European Commission. Tolerability and safety assessments, clinical chemistry, haematological tests and urinalysis, and the measurement of vital signs (blood pressure and heart rate) and ECG were included in the study. All data relating to drug safety were recorded throughout the study.
Moxifloxacin sampling and analysis
On day 1, blood samples (6 mL) were taken from a peripheral vein before and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 and 24 h after start of infusion through an indwelling venous cannula, and on day 3 (steady-state) before and 1, 2, 3, 6 and 24 h after medication. The samples were centrifuged at 2800 g for 5 min at 48C and stored at 2808C until analysis. Additionally, in five patients, where paracentesis was clinically indicated, samples of ascitic fluid (50 mL per sample) were obtained 3 and 6 h after infusion on days 1 and 3. Concentrations of moxifloxacin in serum and ascites samples were determined by the HPLC method with fluorescence detection. 5 The assay was validated intra-and inter-daily according to standard procedures. The lower limit of quantification of moxifloxacin was 0.01 mg/L in serum and ascitic fluid, with coefficient of variation and relative error of ,5% and ,1%, respectively. Precisions and accuracies of other controls in the medium and upper range of the calibration range were better than 15%. Recoveries ranged between 80% and 85% based on spiking solution.
Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis for the data was performed using the WinNonlin software program (WinNonlin version 3.1, Pharsight Corporation, Mountain View, CA, USA). The maximum concentration in plasma (C max ) and time to reach C max (T max ) after drug administration were obtained directly by visual examination of concentration -time data. The area under the plasma concentration -time curve from time zero to infinity (AUC 0 -1 ) was calculated by log-linear trapezoidal rule until the time of last quantifiable plasma concentration and then extrapolated to infinity by using the quotient of the last measurable concentration (C last ) to the terminal-phase rate constant (b). The terminal elimination rate constant (b) was estimated from the slope of terminal exponential phase of the logarithmic plasma concentration -time profile, using at least three data points. The elimination half-life (t 1/2b ) was determined as 0.693/b. The mean residence time (MRT) was calculated AUMC 0 -1 /AUC 0 -1 , where AUMC 0 -1 is the area under the first moment of the concentration -time curve. Total body clearance (CL tot ) was determined as dose/AUC 0 -1 . The steady-state volume of distribution (V ss ) was calculated as a product of MRT and CL tot . All data are presented as median and minimum-maximum ranges. Statistical analysis for differences in pharmacokinetic parameters from day 1 to day 3 was performed using the Wilcoxon signed-rank test. P values ,0.05 were considered significant.
Results
Nine patients (1 woman, 40 years old, and 8 men, aged between 40 and 78 years; median body weight 82 kg, range 68-92 kg) with alcoholic liver cirrhosis and severe hepatic impairment (Child -Pugh class C) were included in the study. The creatinine clearance of the patients varied between 65 and 121 mL/min/1.73 m 2 . No hypoalbuminaemia was observed. All included patients had clinical signs of infection, including leucocytosis and an elevated C-reactive protein. The most common diagnosis was spontaneous bacterial peritonitis (six patients), verified by detection of .250 neutrophils/mL in ascitic fluid. Median length of moxifloxacin treatment was 7 days. Overall tolerability of the treatment with moxifloxacin was good. No serious adverse events were observed. No patient had to be withdrawn from the study. Pharmacokinetic investigations in serum were completed for all nine patients. The serum concentrationtime curves of days 1 and 3 are shown in Figure 1 . All relevant pharmacokinetic parameters after single (day 1) and multiple (day 3) administration are listed in Table 1 . On day 1, serum concentrations of moxifloxacin were highest at the end of the 1 h infusion, with a median of 3.7 mg/L, and decreased progressively during the sampling period, reaching a median of 0.6 mg/L at 24 h. On day 3, serum peak and trough levels were only moderately increased in comparison with day 1, with moxifloxacin concentrations of 3.9 mg/L after 1 h and 0.6 mg/L 24 h after the third infusion (Figure 1 ). The AUC 0 -24 (31.8 versus 37.4 mg . h/L) and AUC 0 -1 (41.9 versus 45.5 mg . h/L) were slightly, but not statistically significantly, increased on day 3. Calculations of terminal elimination half-life, MRT, CL tot and V ss in serum also revealed no significant differences between days 1 and 3 (Table 1 infusion on day 1, and 2.1 mg/L (1.7-2.4 mg/L) 3 h after infusion and 1.9 mg/L (1.5-2.2 mg/L) 6 h after infusion on day 3. There were no significant differences in median moxifloxacin penetration into ascites, calculated as ascites/serum concentration ratio (day 1: 0.6 at 3 h versus 0.9 at 6 h; day 3: 0.7 at 3 h versus 0.8 at 6 h).
Discussion
Although intravenous moxifloxacin is widely used in the treatment of serious hospital infections, no study investigating its single-and multiple-dose pharmacokinetics (PK) in patients with hepatic insufficiency has been published previously. As our results have shown, moxifloxacin can be safely administered to subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh class C) without the need for dose adjustment. The main pharmacokinetic parameters of moxifloxacin such as peak and trough serum concentrations, AUC values, terminal elimination half-life, MRT, total body clearance and volume of distribution in our study were absolutely comparable with previous reports in healthy young and older volunteers. 4, 6 Beyond that, neither statistically significant nor clinically relevant differences were observed between the pharmacokinetic profiles of moxifloxacin on days 1 and 3. A possible explanation for the lack of drug accumulation in our patients might be related to the unique liver metabolism of moxifloxacin alone via glucuronide and sulphate conjugation. According to Stass and Kubitza, 6 54% of a single dose is recovered in stool and urine as metabolite M1 (sulfo metabolite) and M2 (acyl metabolite), 45% of an intravenous dose of moxifloxacin is excreted as unchanged drug, 20% in urine and 25% in faeces. In general, it is well known that chronic liver diseases are associated with impaired metabolism of a number of drugs. 7 However, the degree of impairment varies depending on the type of metabolic reaction involved. Oxidative metabolic reactions, catalysed by a large number of cytochrome P450 isoenzymes, appear to be more affected by chronic liver disease compared, for example, with glucuronidation, an important Phase II reaction catalysed by the uridinediphosphate-glucuronosyltransferases. 8 The cytochrome P450 system is not involved in moxifloxacin metabolism. 4, 6 The second aim of this study was to determine the concentrations of moxifloxacin in ascitic fluid. Here, the median concentrations following a single intravenous dose of 400 mg were 1.4 mg/L at 3 h after the end of infusion and 1.3 mg/L at 6 h after infusion. After the third infusion (day 3), median concentrations in ascites were slightly increased compared with day 1 (2.1 mg/L at 3 h and 1.9 mg/L at 6 h). The median ratios of ascites to serum concentration varied between 0.6 (day 1) and 0.8 (day 3), and were higher than that measured with ciprofloxacin, pefloxacin and ofloxacin. 9 Finally, the question arises as to whether the drug concentration in the ascitic fluid is sufficient to eliminate the bacteria in patients with spontaneous bacterial peritonitis. Fluoroquinolones exert their killing effect in a concentration-dependent manner. 10 Antibiotics that exhibit this pattern of killing generate a higher rate and extent of killing with increasing concentrations. Therefore, the peak of concentration (C max ) and the exposure (AUC) are the most important factors associated with therapeutic efficacy. C max values 10-fold higher than the MIC 90 are usually considered to be effective. 10 In this study, peak concentrations of moxifloxacin in ascitic fluid amounted to 175-to 260-fold of an MIC 90 value of 0.008 mg/L. Thus, effective ascites peak concentrations were achieved for Escherichia coli, which is the most common pathogen in spontaneous bacterial peritonitis (40% to 60% of cases).
1,2 Another important PK/PD parameter for prediction of clinical efficacy in fluoroquinolones is the free AUC 0 -1 /MIC ratio. 10 Because of the limitation of only two available measuring points from the puncture of ascites, this study has not allowed the calculation of AUC in ascitic fluid from time zero to infinity.
In conclusion, this study indicated for the first time that pharmacokinetic parameters of moxifloxacin in patients with advanced liver cirrhosis after single and multiple intravenous dosing differed only marginally from those derived from healthy control groups given in the literature. After multiple dosing, no drug accumulation was observed. Therefore, a dose adjustment is not necessary in cirrhosis patients with severe hepatic impairment. Furthermore, the results of the study show that moxifloxacin penetrated ascitic fluid in cirrhosis patients, achieving and maintaining concentrations higher than the MICs for the common causative pathogens in spontaneous bacterial peritonitis.
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